Thrombin rapidly binds to and saturates rabbit aorta endothelium in vitro, a process that depends on pericellular glycosaminoglycans and that is inhibited by heparin. To characterize the initial adsorption of thrombin to the endothelium in vivo, an enzymatically inactive derivative, FPR-thrombin (i.e., thrombin inactivated by D-Phe-Pro-Arg-chloromethyl ketone), was prepared. The binding characteristics of thrombin and FPR-thrombin to heparin-Sepharose and to the endothelial surface of rabbit aorta segments in vitro were compared. From these experiments, we concluded that FPR-thrombin mimicked, qualitatively, the binding of thrombin to the endothelium. When injected intravenously, I251-FPR-thrombin was removed rapidly from the rabbit circulation (T112, -1.4 minutes) and simultaneously was adsorbed by the vascular endothelium, particularly in the lung. By injecting heparin (1,000 units/kg i.v.) before '25I-FPR-thrombin, adsorption by the aorta endothelium at 30 minutes after injection was reduced by 90%, and T1/2 was increased to approximately 3.4 minutes. Heparin, administered at various times after '25I-FPR-thrombin, liberated a significant proportion of '25I-FPR-thrombin from the endothelial surface into the plasma compartment as shown by a pronounced "spike" on the plasma curve, a concomitant loss of radioactivity from the lung and from the aorta endothelium, and analysis of the radioactive components of plasma taken before and after heparin injection. Thus, FPR-thrombin was cleared rapidly from the circulation, and endothelium-bound FPR-thrombin was released into the circulation by heparin. (Circulation Research 1990;67:221-229) Specific binding sites for thrombin have been indicated on the cell membrane of cultured endothelial cells12 and of endothelial cells of the intact rabbit aorta.3,4 In addition, we found that thrombin binding was inhibited by heparin and that thrombin adsorbed by the endothelium was largely displaced by heparin.3 Furthermore, the destruction of thrombin binding sites of the endothelium by glycosaminoglycan-degrading enzymes, particularly chondroitinase ABC,5 coupled with reports that prot-
Thrombin rapidly binds to and saturates rabbit aorta endothelium in vitro, a process that depends on pericellular glycosaminoglycans and that is inhibited by heparin. To characterize the initial adsorption of thrombin to the endothelium in vivo, an enzymatically inactive derivative, FPR-thrombin (i.e., thrombin inactivated by D-Phe-Pro-Arg-chloromethyl ketone), was prepared. The binding characteristics of thrombin and FPR-thrombin to heparin-Sepharose and to the endothelial surface of rabbit aorta segments in vitro were compared. From these experiments, we concluded that FPR-thrombin mimicked, qualitatively, the binding of thrombin to the endothelium. When injected intravenously, I251-FPR-thrombin was removed rapidly from the rabbit circulation (T112, -1.4 minutes) and simultaneously was adsorbed by the vascular endothelium, particularly in the lung. By injecting heparin (1,000 units/kg i.v.) before '25I-FPR-thrombin, adsorption by the aorta endothelium at 30 minutes after injection was reduced by 90%, and T1/2 was increased to approximately 3.4 minutes. Heparin, administered at various times after '25I-FPR-thrombin, liberated a significant proportion of '25I-FPR-thrombin from the endothelial surface into the plasma compartment as shown by a pronounced "spike" on the plasma curve, a concomitant loss of radioactivity from the lung and from the aorta endothelium, and analysis of the radioactive components of plasma taken before and after heparin injection. Thus, FPR-thrombin was cleared rapidly from the circulation, and endothelium-bound FPR-thrombin was released into the circulation by heparin. (Circulation Research 1990; 67:221-229) Specific binding sites for thrombin have been indicated on the cell membrane of cultured endothelial cells12 and of endothelial cells of the intact rabbit aorta. 3, 4 In addition, we found that thrombin binding was inhibited by heparin and that thrombin adsorbed by the endothelium was largely displaced by heparin.3 Furthermore, the destruction of thrombin binding sites of the endothelium by glycosaminoglycan-degrading enzymes, particularly chondroitinase ABC,5 coupled with reports that prot-amine, a cationic protein that binds strongly to all classes of glycosaminoglycans,6'7 inhibited thrombin binding to the endothelium8 have provided support for the view that pericellular glycosaminoglycan chains bind thrombin directly to the endothelial cell.
Esmon et al9"10 have described an endothelial cell membrane receptor, thrombomodulin, that binds thrombin for the purpose of activating protein C; activated protein C is a potent anticoagulant that specifically inhibits coagulation factors Va and VIIIa (reviewed in Reference 11). Bourin et al'2 reported that two forms of thrombomodulin are present in rabbit lung. An acidic form contains a heparinrelated O-glycan that is directly involved in binding thrombin to thrombomodulin. Digestion with chondroitinase ABC converts the acidic form into the nonacidic form of thrombomodulin. 13 In the following account, we have explored further our earlier observation (namely, that heparin inhibits thrombin binding by the endothelium in vitro) to determine whether FPR-thrombin (i.e., thrombin inactivated by D-Phe-Pro-Arg-chloromethyl ketone) is rapidly adsorbed by the vascular endothelium in vivo and, if so, whether intravenous heparin can displace FPR-thrombin bound to the endothelium.
Materials and Methods

Materials
Thrombostat, a crude bovine thrombin prepara- Antibody to FPR-thrombin was raised in a rabbit by injecting 0.4 mg FPR-thrombin, initially in 0.5 ml complete Freund's adjuvant and subsequently in 0.5 ml incomplete Freund's adjuvant, intramuscularly at 2-week intervals. Blood (10 ml) was taken from an ear artery into acid-citrate-dextrose (blood: acid-citrate-dextrose =8.5 vol:1.5 vol) and stored frozen (-40°C) as plasma.
Preparation and Punification of Proteins
Procedures for isolating purified bovine athrombin and preparing FPR-thrombin by using FPR-chloromethyl ketone have been described previously. 14 
Punrty of Protein Preparations
The purity of each protein preparation was assessed before and after reduction with ,Bmercaptoethanol by using polyacrylamide gel electrophoresis (PAGE; 7.5% or 10% acrylamide) in the presence of 0.2% sodium dodecyl sulfate (SDS) relative to standard proteins. 16 In addition, for each protein sample, the radiolabeled protein was inplu4ded in the load for SDS-PAGE. After staining the fixed gel with 0.1% Coomassie blue and destaining, the gel was immersed briefly in 10% glycerol (aqueous) and heat dried in vacuo onto Whatman 3MM paper (Clifton, N.J). The dried gel was then exposed (5-15 minutes) to Kodak X-AR5 film (Rochester, N.Y.) at 230 C Preparations of both FPR-thrombin and 251I-FPR-thrombin contained only a-and f-thrombins (ratio of approximately 9: 1) of M, 36 kDa and 28 kDa, respectively. Albumin electrophoresed as a single band (Mr, 65 kDa), which was coincident with "1I-albumin.
Iodination of Proteins
The procedure using solid phase lactoperoxidase/ glucose oxidase (Enzymobeads) was that described by the supplier (Biorad). Approximately 30-50 pg protein was iodinated for 30 minutes at 230 C. After centrifugation, a known volume of supernatant containing the radiolabeled protein was dialyzed against four changes of HEPES-buffered MEM, pH-7.4, over 18 hours at 40 C as described peYviouly.4,'5 Al radiolabeled proteins were stored at 40 C and were used for experiments within 5 days of iodinatin. Content of free iodide was assessed after precipitation with trichloroacetic acid; "'I-FPR-thrqmbin and 13'I-albumin preparations contained 2-3% anpd >1% free 125I-iodide, respectively. Chromatographic Properties of the Radiolabeled Thrombins on Heparin-Sepharose A heparin-Sepharose17 column (13 xl cm) was equilibrated with 0.01 M Tris HCl-Q15 M. NaCi (pH 7.4) at 23°C. After each sample (<1 ,g radiolabeled protein in 1 ml buffer containing 40 mg RSA as carrier) was loaded, the column was washed with 100 ml buffer and was then eluted with a linear gradient consisting of 100 mrl buffer in the mi-ng chamber and 100 ml limit solvent (0,01 M Tris HCl=0.15 M NaCl [pH 7.4], containing 2Q0 mg hoparin/uml). In one chromatography, 200 RU thrombin was included in the load for comparison with '251-thrombin. A molecular weight of 15,000 has been used for all molar calculations of heparin.
Comparison of I251-FPR-Thrombin and 13I-Thrombin
Binding by the Rabbit Aorta Endothelium In Vitro Studies were conducted by using techniques derbed previ ly.4 riey, thoraci artas were excised frO New Zealand White male rabbits (2.5-3.0 kg) after cannulation and ---ado nuimtion through the left carotid artery. Each isolatd vessel was cleared of adherent connective tissue and divided into eight 1-cm segments. The aorta segment$ were incubated (2-20 minutes, 370 C) in 1 ml MEM cotaining 4% rabbit serum albumin (R$AMEM) and the radiolabeled thrombins. After the aora eg was rinsed (1 minute, 370 C) with 4 ml MEM, it was slit longitudinally and opened flat with the endothelium uppermost. The surface area was measured with a digital planimeter (Lasico, Los Angeles), and the endothelial and subendothelial (intima-media only) layers were separated from the adventitia by using cellulose acetate paper18 and Bergh cilia forceps (Stevens, Bramalea, Canada), respectively. These isolated vessel layers, together with a sample of the incubate, were measured for radioactivity content using a Beckman Biogamma counter (Fullerton, California).
In some experiments, various concentrations of FPR-thrombin, thrombin, or heparin were added to the incubate to compare their individual properties as an inhibitor of radiolabeled FPR-thrombin and/or thrombin binding. More details of these experiments are included in the legends to the figures. Binding of '25I-FPR-Thrombin by the Rabbit Aorta Endothelium In ivo Radiolabeled proteins (5-10 ,ug) were injected into New Zealand White male rabbits through a marginal ear vein. Blood samples (1 ml) were taken at 5 minutes after injection and at regular intervals for up to 5 hours to obtain a plasma clearance curve. At a selected time after injection, each rabbit was anesthetized (39-43 mg sodium pentobarbital/kg), cannulated, and exsanguinated. The thoracic aorta was excised, and the endothelial and subendothelial layers of the eight 1-cm segments were separated and measured for area and radioactivity content. The location and integrity of "1I-FPR-thrombin adsorbed by the endothelium was tested by intravenously injecting 1 ml heparin (1,000 units/kg), a polyspecific antiserum to the protein, or saline at various times after the radiolabeled protein was injected, followed by blood sampling at 5, 15, and 30 minutes afterward. In some rabbits, heparin (1,000 units/kg) was injected 5 minutes before injection of 1`I-FPR-thrombin to measure the effect of heparin on the plasma clearance of this protein and its adsorption by the aorta endothelium.
Organ Distribution of FPR-Thrombin In Vivo
Known quantities of "1I-FPR-thrombin and "'I-RSA were coinjected intravenously into rabbits. Blood samples (1 ml) were taken immediately before exsanguination. The entire aorta, kidneys, lungs, two lobes of liver, spleen, and a portion of ileum were excised. Only the intima-media layer of the aorta was taken for analysis. 
Analysis of Plasma Samples
Containing 125I-FPR-Thrombin Plasma samples, taken before and at 5, 10, and 30 minutes after heparin injection, were reduced by A3-mercaptoethanol and analyzed by SO)S-PAGE followed by protein staining gel drying, and finally, autoradiography with Kodak`X-AR film for 27 days at -40' C.
Results
Chromatogra.phi Comparison of FPR=Trormbin and Thrombin on Hepann-Sepharose
In Figure 1 , profiles are shown of '1I-FPRthrombin and "'1-thrombin cluted from a heparin-Sepharose column with a linear gradient of heparin. From three chromatographic runs thrombin and FPR-thrombin were eluted by 58.6 mM and 61 inM heparin, respectively. Native thrombin (not shown) ran coincidentally with radiolabeled thrombin. Comparison of the Binding Properties of Thrombin With FPR-Thrombin for the Rabbit Aorta Endothelium In Vitro FPR-thrombin was compared with thrombin as a competitive inhibitor of "21I-thrombin uptake by the aorta endothelium (Figure 2a ). By using 6.9 nM '25I-thrombin, 50% inhibition of binding was obtained by 8.9 nM FPR-thrombin or 35.5 nM thrombin.
Adsorption of "25I-FPR-thrombin by the aorta endothelium was compared with that of '311-thrombin over a 20-minute incubation, Adsorption wa initially rapid, and at 5 minutes, the enclthelium was saturated with '311-thrombin, whereas binding of`P FPR-thromibin continued to increase at a relatively slower rate (Figure 2b ). Both thrombin and FPRthrombin passed through the endothelium and accumulated in the subendothelium. The addition of heparin to the incubate inhibited binding of both "L-thrombin and I251-FPR-thrombin: 50% inhibition was obtained at 0.40 pgM and 3.95 ,uM heparin, respectively (Figure 3a ). Furthermore, heparin de- FPR-thrombin and thrombin as inhibitors of I251-thrombin binding by the endothelium. Competition experiments were conducted by using FPR-thrombin and thrombin with vessel segments from the same aorta. I25-thrombin (6.9±1.8 pmol) was added to 1 ml of 4% rabbit serum albumin-minimal essential medium (RSA-MEM) containing various quantities (5 -1,050 pmol) of either FPR-thrombin or thrombin immediately before an aorta segment was added. The tissue was incubated for 10 minutes (370 C) and then rinsed briefly for 1 minute in MEM (4 ml). Panel b: Adsorption ofFPR-thrombin and thrombin by the endothelium and subendothelium of the aorta. A mixture (1-2 p.l) of 125I-FPR-thrombin and 131Ithrombin were added to 1 ml of 4% RSA-MEM (final concentration of thrombins, 4.9-9.0 pmol/ml) immediately before a 1-cm segment of aorta was added. Measurement of aorta surface area, separation of vessel layers, and measurement of radioactivity content are described in the text. Results are given as endothelium-bound FPR-thrombin (o), subendotheliumbound FPR-thrombin (A), endothelium-bound thrombin (e), and subendothelium-bound thrombin (A).
sorbed both radiolabeled proteins from the endothelial surface (Figure 3b ): 50% of bound thrombin and FPR-thrombin was liberated by 0.32 MuM and 3.93 gM heparin, respectively. From these experiments, we concluded that binding sites for FPR-thrombin on the endothelium were qualitatively similar to those for native thrombin although the affinities of FPR-thrombin and throm- pmol/ml, immediately before aorta segments were added.
Incubation conditions: 10 minutes, 370 C. Panel b: Desorption: Aorta segments were exposed for 10 minutes to 12sI-FPR-thrombin (o) and`31-thrombin (@) in 1 ml of 4% RSA-MEM (10 minutes), rinsed (1 minute), and then exposed to 1 ml of 4% RSA-MEM alone or containing heparin (0.06 pg-10 mg, 5 minutes). Data are calculated as the mean (±SD) value for six to eight segments taken from three or four aortas. Where no error bars are shown, value shown is the mean of two segments from one aorta.
bin for these binding sites were clearly different. Further support for this conclusion was obtained by pretreating aorta segments with protease-free chondroitinase ABC (5 IU/ml, 10 370 C) before the treated vessel was rinsed (1 minute) and then exposed to radiolabeled samples of FPRthrombin and thrombin. This treatment reduced endothelial binding of both FPR-thrombin and thrombin by 75-80% compared with that of untreated segments taken from the same aorta.
Fate of 125I-FPR-Thrombin In Vivo
After intravenous injection, 125I-FPR-thrombin was cleared rapidly (T1/2, -1.4 minutes) from the rabbit circulation. Indeed, the first blood sample, taken 5 minutes after injection, contained only 7.1 (±3.2)% of the calculated dose; at 3-5 hours after injection the plasma radioactivity had diminished to 2-3% of the dose (Figure 4a ). By injecting heparin (1,000 units/kg i.v.) immediately before injection of 1251_ FPR-thrombin, clearance of the radiolabeled protein was decreased considerably (T1/2, -3.4 minutes), the 5-minute blood sample containing 33-37% of the calculated dose. However, by 2 hours, the level of plasma radioactivity in heparinized rabbits differed insignificantly from unheparinized rabbits. The introduction of heparin at various times after injection of 125I-FPR-thrombin released significant radioactivity into the circulation (Figure 4b ). The extent of release appeared to diminish as the interval after injection of the 125I-FPR-thrombin dose lengthened. A similar "spike" of '"I-FPR-thrombin in the circulation was observed when rabbit antiserum to bovine FPR-thrombin was injected (Figure 4c ). However, no release of radioactivity was observed when saline was injected.
Measurement of the radioactivity content of the aorta wall ( Figure 5 ) indicated that the endothelium adsorbed FPR-thrombin rapidly from the circulation. Uptake of radioactivity by the endothelium preceded '25I-FPR-thrombin was allowed to circulate for various times before the rabbit was killed and exsanguinated. After recovery of the aorta, the quantity of adsorbed FPR-thrombin (o) was calculated from the radioactivity content of the endothelium as the percentage of bound radioactivity per square centimeter per milliliter of blood radioactivity at exsanguination. Each symbol denotes one aorta (±SD; n=8 segments). In some experiments, heparin (1,000 units/kg) was administered at 30 minutes before the rabbit was killed and exsanguinated (A), or in a control experiment (A), heparin was given intravenously to one rabbit immediately before the 12I-FPR-thrombin dose (circulation time, 30 minutes).
its accumulation in the subendothelium (data not shown). After a surge of endothelial binding when '25I-FPR-thrombin was injected, the proportion of 125I radioactivity associated with the endothelium declined slowly during the ensuing 2-3-hour period, reflecting the similarly slow fall in plasma radioactivity over the same period (Figure 4a ).
During the first hour after injection of 1251 FPR-thrombin, administration of heparin displaced up to 90% of the radioactivity bound to the aorta endothelium ( Figure 5 ). As the time interval increased, the proportion of heparin-releasable radioactivity decreased such that, at 3 hours postinjection, only 10-20% was displaced by heparin.
Analysis of SDS-PAGE and autoradiography (Figure 6 ) of the circulating radioactive products displaced by heparin from the vascular wall at 15 minutes after injection of '"I-FPR-thrombin revealed, in addition to some radioactivity that did not enter the gel, two major components, approximately 30 kDa and <10 kDa, corresponding, presumably, to the B and A chains of the enzyme, respectively. 'I-FPR-thrombin and FPRthrombin displayed a similar two-band appearance after electrophoresis. Distribution of 125I-FPR-Thrombin in the Major Organs of the Rabbit After a short (-10-minute) circulation time, 1251-FPR-thrombin, coinjected with I3'I-RSA, had accu-mulated preferentially in the lungs and, to a much lesser extent, in the spleen and other organs relative to 131I-RSA (Table 1) .
The pattern of organ distribution of '1I-FPRthrombin after a circulation time of 10 minutes was disturbed significantly if heparin (1,000 units/kg) had been injected intravenously at 5 minutes before the radiolabeled proteins ( Table 1 ). Assuming that heparin had no major effect on the distribution of 131I-RSA, the uptake of FPR-thrombin by the lung was reduced by more than 50%, whereas the content of FPR-thrombin in the blood was increased threefold and the uptake by the other organs was increased by 20-100%.
Discussion
Similarities in the binding of thrombin and DIPthrombin (i.e., thrombin inactivated by diisopropyl fluorophosphate) toward cultured vascular endothelial cells have been reported previously.1,2'19 Furthermore, the rapid clearance of '25I-DIP-thrombin has been observed from the circulation of the rabbit20 and mouse.21 In this study, we have compared the adsorption of 1251-FPR-thrombin and "'1-thrombin by the endothelium and subendothelium of aorta segments in vitro (Figure 2b) . From the report of Lollar et al,19 the initial rapid binding of thrombin by cultured human endothelial cells is followed by a slow binding phase for up to 2 hours, whereas DIP-thrombin rapidly saturates the binding sites and remained at a steady state. The authors conclude that cell-bound, active thrombin may be required for slow binding and for protein transport by pinocytosis. In our experimental system, incubation for 20 minutes gives a pattern of binding that contrasts with that determined by Lollar et al,19 that is, thrombin binds and rapidly assumes a steady state, whereas FPRthrombin, after the rapid binding phase, continues to bind slowly (Figure 2b) . We have no ready answer to explain these different results other than identifying those differences between the two studies with respect to experimental design (e.g., use of cultured human umbilical vein cells compared with rabbit arterial endothelium; human versus bovine thrombin; DIPversus FPR-thrombin). However, that 1251_ FPR-thrombin accumulates in the aorta subendothelium at a faster rate than "311-thrombin ( Figure 2b) suggests that enzymatic activity is not essential for transport of thrombin across the endothelium although the route of transportation (i.e., intracellular or intercellular) has not been determined.
Both FPR-thrombin and thrombin competed with '1I-thrombin for binding sites on the endothelium (Figure 2a ), whereas pretreatment of the aorta surface with chondroitinase ABC largely abolished binding of 1251-FPR-thrombin and 131-thrombin by the endothelium. Heparin inhibited the binding of 1'PI-FPR-thrombin and 131I-thrombin to the endothelium (Figure 3a ) and displaced these bound proteins from the endothelium (Figure 3b ) and from heparin-Sepharose (Figure 1 ). From these experiments, we concluded that endothelial binding of FPRthrombin is qualitatively similar to that of thrombin and that use of 125I-FPR-thrombin in vivo would largely simulate the interaction of thrombin with the endothelium. FPR-thrombin introduced to the rabbit circulation was cleared rapidly from the vascular pool ( Figure  4a ) and adsorbed by the endothelial surface ( Figure  5 , Table 1 ). Heparin spontaneously released FPRthrombin from the endothelial surface as shown by 1) rebound of radioactivity into the plasma (Figures  4b and 6 ) and 2) the decreased radioactivity of the lung (Table 1 ) and, particularly, the aorta endothelium ( Figure 5 ).
From the data in Table 1 , heparin in the circulation either inhibited binding of FPR-thrombin by the lung endothelium or, as shown in Figure 4b , displaced endothelium-bound FPR-thrombin. The noncovalent complex, heparin-FPR-thrombin, will not react with plasma antithrombin III (ATIII) and, presumably, dissociates in the circulation. As the heparin level decreases,22 FPR-thrombin will be readsorbed by the vascular endothelium (see Figure  4a ; also the solid triangle in Figure 5 ).
The proportion of 251I-FPR-thrombin that was available for desorption by heparin into the plasma 6 p, 6 7 ther blood samples were taken at 21, 31 for radioactivity content. The corrected 1251/1311 ratios for plasmas and organ homogenates were compared with that of the initial dose (adjusted to 1.0) and are expressed as the mean (±SD). By using kinetic data of heparin in the circulation of the rabbit22 and assuming a blood volume of 56 ml/kg, the concentration of heparin at the time of injection of radiolabeled proteins was calculated to be approximately 10 units/mI blood. FPR-thrombin, a thrombin derivative deactivated by D-Phe-Pro-Arg-chloromethyl ketone;
RSA, rabbit serum albumin. decreased during the initial 1-2 hours after injection (Figure 4b ). This decrease mirrored an increase in radioactivity associated with the heparin-treated aorta endothelium over the same time interval (Figure 5 ). By comparison, the control aorta endothelium (i.e., nonheparin treated) showed a rapid uptake of 125I-FPR-thrombin that decreased slowly to the 40% level during the first hour after injection. The difference in radioactivity content between the control and heparin-treated aorta endothelium at 30 minutes postinjection ( Figure 5 ) indicates that heparin displaced up to 90% of the adsorbed 1251I-FPR-thrombin from the endothelium; this difference diminished until, at 90 minutes after injection, the quantities of radioactivity bound by untreated and heparin-treated aorta endothelium were similar. Radioactivity, which was not desorbed by heparin, is assumed to be 1251-FPR-thrombin that had been slowly endocytosed by the endothelial cells, either for lysosomal degradation23,24 or for transport to the subendothelium (M.W.C. Hatton and S.L. Moar, unpublished data).
The observation that heparin (at a relatively high plasma concentration) decreased 125I-FPR-thrombin binding by the lung endothelium (Table 1) , coupled with the report25 that FPR-thrombin competes for thrombin binding sites on thrombomodulin, suggests that heparin may also inhibit thrombin binding to, or displace bound thrombin from, thrombomodulin directly. Thrombomodulin in the lung is present in high concentrations, relative to other organs,26 and is probably the principal binding site for thrombin on the lung endothelium.9 Indeed, if local thrombin production at the endothelial surface is sufficient for thrombin to associate with thrombomodulin, then a state of anticoagulation is brought about through activation of protein C. Inactivation of thrombomodulin-bound thrombin by plasma AT1I125,27 would destroy this anticoagulant state, although Delvos et a128 reported that endothelial cell-bound thrombin may be protected against ATIII. Interestingly, if heparin at high concentrations does displace thrombin from the thrombomodulin binding site in vivo, heparin may conceivably be acting as a procoagulant rather than an anticoagulant. The action of heparin in displacing cell-surfacebound thrombin and the presence of heparin-binding sites in many growth factors29 may explain observations that heparin (or related species) influences cell growth and migration. For example, heparin can enhance endothelial cell growth in culture,30 promote angiogenesis31 or, in the presence of cortisone, inhibit angiogenesis,32 and inhibit the growth of arterial smooth muscle cells in vitro33 or in vivo. 34 Conceivably, heparin may displace growth factors from glycosaminoglycan-binding sites on cell surfaces or the extracellular matrix. Thrombin itself is reported to be mitogenic35 for vascular cells; displacement of thrombin from, or inhibition of thrombin binding to, the cell surface by heparin would presumably diminish cell proliferation that may otherwise have been induced by surface-bound thrombin.
